Market barriers affect over a quarter of melanoma prescriptions. Is your brand losing out?
In the US, where market barriers affect more than a quarter of all melanoma prescriptions, the top brand has a narrow lead over its 2nd, 3rd, and 4th-place rivals. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: Melanoma (US).
Based on a survey of 100 oncologists and dermato-oncologists, the report covers 8 major therapies from Amgen, Bristol-Myers Squibb, Merck & Co., Novartis, and Roche. Handy graphs and charts reveal which of 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Not your market? Click here to see the EU5 report
Market Access Impact: Melanoma (US) explores key issues affecting melanoma drug manufacturers. You’ll learn:
How barriers affect market access:
How barriers affect your brand:
We surveyed 100 US-based medical oncologists and dermato-oncologists, chosen from the largest community of validated physicians in the world.
All respondents have:
We conducted the survey between January 10th and 16th, 2017.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.